Subcutaneous administration in horses involves the delivery of medication or other substances into the tissue layer between the skin and muscle. This method is used for various therapeutic and preventative treatments, including vaccinations, analgesics, and fluid administration. The technique requires careful consideration of factors such as needle size, injection site, and volume of the substance to ensure effective absorption and minimize discomfort or complications. Subcutaneous administration is often chosen for its ease of application and potential for sustained release of medication. This page compiles peer-reviewed research studies and scholarly articles that explore the methodology, efficacy, and applications of subcutaneous administration in equine veterinary practice.
Byars TD, Greene CE, Kemp DT.Warfarin-induced anticoagulation and reversal of the induced anticoagulation by vitamin K1 were evaluated in 4 mature horses. Each horse was given warfarin IV until the prothrombin (PT) time was prolonged by approximately 1.5 times the predosing base-line value. In experiment 1, we evaluated the time required for PT to return to the predosing value (PT reversal time) after warfarin administration was discontinued. Between each experiment, a 1-week rest period was allowed. In experiment 2, two doses of vitamin K1 (100 mg/dose) were administered IM 6 hours apart, and the PT was monitored hourly ...
Douglas RH, Ginther OJ.Several experiments indicated that prostaglandin F2alpha (PGF2alpha) has luteolytic and abortifacient properties in mares. A single subcutaneous injection of 1-25 mg PGF2alpha on Day 6 of dioestrus was as effective as 10 mg PGF2alpha in inducing luteolysis. Oestrus and ovulation appeared to be synchronized when a single injection of 1-25 mg PGF2alpha was given on Days 7, 10 or 13 after ovulation but not on Days 1 or 4 after ovulation or on Day 2 of oestrus. Intramuscular administration was as effective as subcutaneous administration and 1-25 mg PGF2alpha was the minimal effective systemic dose...
Oxender WD, Noden PA, Bolenbaugh DL, Hafs HD.To determine the minimal effective dose of prostagiandin (PGF2alpha; tromethamine salt) given subcutaneously (SC), mares of mixed breeding (400 kg av body weight) were given 2-, 3-, 5-, and 10-mg doses from 7 to 9 days after ovulation. In some but not all mares given doses of 2 and 3 mg of PGF2alpha, luteolysis occurred, but doses of 5 or 10 mg of PGF2alpha were luteolytic in all mares. The 10-mg dose of PGF2alpha did not cause luteolysis in mares 1 day after ovulation, and caused luteolysis in only 2 of 5 mares on day 3 after ovulation. The same dose of PGF2alpha, however, caused luteolysis i...
Lees P, Landoni MF, Giraudel J, Toutain PL.This review summarises selected aspects of the pharmacokinetics (PK) and pharmacodynamics (PD) of nonsteroidal anti-inflammatory drugs (NSAIDs). It is not intended to be comprehensive, in that it covers neither minor species nor several important aspects of NSAID PD. The limited objective of the review is to summarise those aspects of NSAID PK and PD, which are important to an understanding of PK-PD integration and PK-PD modelling (the subject of the next review in this issue). The general features of NSAID PK are: usually good bioavailability from oral, intramuscular and subcutaneous administ...
Di Cesare F, Rabbogliatti V, Draghi S, Amari M, Brioschi FA, Villa R, Ravasio G, Cagnardi P.The inclusion of dexmedetomidine (DEX) within a balanced general anaesthesia protocol is effective in improving the clinical outcome and recovery quality of anaesthesia in horses. This study aimed to determine the pharmacokinetic profile of DEX following repeated subcutaneous (SC) administration at 2 µg/kg every 60 min till the end of the procedure in comparison to intravenous constant rate infusion (CRI) at 1 µg/kg/h in anaesthetized horses undergoing diagnostic procedures up to the end of the diagnostic procedure. Results: In the CRI and SC groups DEX maximum concentrations (Cmax) were ...
Beermann A, Clottu O, Reif M, Biegel U, Unger L, Koch C.Equine sarcoids (ES) are the most common cutaneous tumors in equids. Systemic treatment options are sparse. Subcutaneous (SC) injections of Viscum album extract (VAE) demonstrate efficacy as a systemic treatment directed against ES. Objective: To critically assess the therapeutic efficacy of orally administered VAE. Methods: Forty-five ES-affected, privately owned, 3-12 year-old horses. Methods: A 3-armed randomized placebo-controlled, double-blinded study was conducted in a double-dummy design. Horses were subjected to oral administration and SC injections of either VAE or placebo (VAE oral...
Brandon AM, Williams JM, Davis JL, Martin EG, Capper AM, Crabtree NE.To determine the pharmacokinetics (PK) of metoclopramide administered via intravenous continuous rate infusion (IV CRI) and subcutaneous (SC) bolus and evaluate for gastrointestinal motility and adverse side effects. Methods: Experimental study; randomized, crossover design. Methods: Six healthy adult horses. Methods: Each horse received metoclopramide via IV CRI (0.04 mg/kg/h for 24 h) and SC bolus (0.08 mg/kg once), with ≥1 week washout period between. Plasma was analyzed by UPLC-MS/MS. Compartmental modeling was used to determine PK parameters for each treatment; nonparametric sup...
